Trial · NCT07890168
Integrated Assessment of Immune-Inflammatory and Metabolic Biomarkers for Prediction of Coronary No-Reflow Following Primary PCI in STEMI Patients
NCT07890168, Recruiting, Sohag University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Integrated Assessment of Immune-Inflammatory and Metabolic Biomarkers for Prediction of Coronary No-Reflow Following Primary PCI in STEMI Patients. Trials, record NCT07890168. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07890168
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Integrated Assessment of Immune-Inflammatory and Metabolic Biomarkers for Prediction of Coronary No-Reflow Following Primary PCI in STEMI Patients
- NCT number
- NCT07890168
- Status
- Recruiting
- Enrollment
- 400 participants, estimated
- Lead sponsor
- Sohag University
- Conditions
- Integrated Assessment, Immune-Inflammatory, Metabolic Biomarkers, Coronary No-Reflow, Primary Percutaneous Coronary Intervention, ST Segment Elevation Myocardial Infarction
- Interventions
- Assessment of immune-inflammatory and metabolic biomarkers
- First posted
- 2026-10-22
- Last updated
- 2026-10-22
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Predictive performance of the Systemic Immune-Inflammation Index (SII) for coronary no-reflow | During the primary percutaneous coronary intervention (Day 1). | Predictive performance of admission Systemic Immune-Inflammation Index (SII), calculated as platelet count × neutrophil count / lymphocyte count, for coronary no-reflow following primary percutaneous coronary intervention (PCI), assessed using the area under the receiver operating characteristic (ROC) curve. |
| Secondary | Occurrence of coronary no-reflow following primary percutaneous coronary intervention | Day 1, immediately at the end of primary percutaneous coronary intervention | Percentage of participants with coronary no-reflow, defined as final thrombolysis in myocardial infarction (TIMI) flow grade \<3 and/or myocardial blush grade ≤1 at the end of primary percutaneous coronary intervention (PCI), in the absence of mechanical obstruction such as dissection, residual stenosis, or spasm. |
| Secondary | Predictive performance of the Triglyceride-Glucose index for coronary no-reflow | Day 1, at the end of percutaneous coronary intervention | Area under the receiver operating characteristic (ROC) curve for admission triglyceride-glucose (TyG) index in predicting coronary no-reflow following primary percutaneous coronary intervention (PCI). TyG is calculated as ln \[triglycerides (mg/dL) × fasting glucose (mg/dL) / 2\] |
| Secondary | Predictive performance of the uric acid-to-HDL cholesterol ratio (UHR) for coronary no-reflow | Day 1, at the end of percutaneous coronary intervention | Area under the ROC curve for admission uric acid-to-HDL cholesterol ratio (UHR) in predicting coronary no-reflow following primary percutaneous coronary intervention (PCI). UHR is calculated as serum uric acid divided by HDL cholesterol. |
| Secondary | Occurrence of in-hospital heart failure | Until discharge or death during the index hospitalization (up to 30 days) | ercentage of participants who develop heart failure during the index hospitalization. Its association with admission immune-inflammatory and metabolic biomarkers will be evaluated. |
| Secondary | Occurrence of in-hospital malignant arrhythmias | Until discharge or death during the index hospitalization (up to 30 days) | Percentage of participants who experience malignant arrhythmias during the index hospitalization. Their association with admission immune-inflammatory and metabolic biomarkers will be evaluated. |
| Secondary | Occurrence of in-hospital cardiogenic shock | Until discharge or death during the index hospitalization (up to 30 days) | Percentage of participants who develop cardiogenic shock during the index hospitalization. Its association with admission immune-inflammatory and metabolic biomarkers will be evaluated. |
| Secondary | Occurrence of in-hospital reinfarction | Until discharge or death during the index hospitalization (up to 30 days) | Percentage of participants who experience reinfarction during the index hospitalization. Its association with admission immune-inflammatory and metabolic biomarkers will be evaluated. |
| Secondary | All-cause in-hospital mortality | Until discharge or death during the index hospitalization (up to 30 days) | Percentage of participants who die from any cause during the index hospitalization. Its association with admission immune-inflammatory and metabolic biomarkers will be evaluated. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07890168
GET https://conductscience.org/api/trials/v1/NCT07890168/registered